- Trials with a EudraCT protocol (44,343)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (18,700)
44,343 result(s) found.
Displaying page 1,341 of 2,218.
EudraCT Number: 2005-002701-23 | Sponsor Protocol Number: SK200504, 28.04.2005 | Start Date*: 2005-08-14 |
Sponsor Name:Siegfried Kasper, O.Univ.Prof.Dr.Dr.h.c. | ||
Full Title: Escitalopram versus Citalopram Treatment effects on cortical and subcortical activity assessed by pharmacological fMRI | ||
Medical condition: Healthy volunteers | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2004-003238-32 | Sponsor Protocol Number: v1 | Start Date*: 2004-12-13 |
Sponsor Name:Dept. of Clinical Pharmacology | ||
Full Title: Effect of pioglitazone on portal and systemic hemodynamics in patients with advanced cirrhosis | ||
Medical condition: Cirrhosis of the liver | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2005-000547-28 | Sponsor Protocol Number: 070774 | Start Date*: 2006-01-15 |
Sponsor Name:Department of Psychiatry; Section of Sleep Research and Pharmacopsychiatry | ||
Full Title: EEG and ERP tomography by means of LORETA (Low-Resolution Brain Electromagnetic Tomography) identifying essential brain regions for vigilance and cognition in narcolepsy: double-blind, placebo-cont... | ||
Medical condition: Patients complaining of excessive daytime sleepiness will be recruited from our sleep clinics and will be subjected to neuropsychiatric, physical, laboratory and neurophysiological screening examin... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2005-004060-24 | Sponsor Protocol Number: Glaucoma Xalacam /Combigan | Start Date*: 2005-11-24 |
Sponsor Name:Department of Clinical Pharmacology | ||
Full Title: A double-masked randomized cross-over study comparing the effect of Xalacom (latanoprost/timolol) and Combigan (brimonidine/timolol) fixed combination on intraocular pressure and ocular blood flow ... | ||
Medical condition: Glaucoma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2006-006982-17 | Sponsor Protocol Number: 05.09.2006 | Start Date*: 2007-07-12 | |||||||||||
Sponsor Name:Division of Special and Environmental Dermatology | |||||||||||||
Full Title: UVA 1 therapy versus 5-MOP UVA photochemotherapy for patients with severe generalized atopic dermatitis | |||||||||||||
Medical condition: Severe generalized atopic dermatitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-001704-23 | Sponsor Protocol Number: PHPT_002/08 | Start Date*: 2009-09-03 | |||||||||||
Sponsor Name:Medizinische Universität Wien, Universitätsklinik für Chirurgie | |||||||||||||
Full Title: Primary hyperparathyroidism: does a systematic treatment improve the calcium and bone metabolism after successful surgery? – Part II Systematic treatment of patients with neither osteopenia nor os... | |||||||||||||
Medical condition: Hypothesis: Calcium and vitamin D intake after surgery for PHPT protects the bone by keeping PTH in the normal range (less secondary, reactive hyperparathyroidism), prevents hungry bone- syndrome a... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-004614-18 | Sponsor Protocol Number: BPR-PIP-001 | Start Date*: 2014-07-30 | ||||||||||||||||
Sponsor Name:Basilea Pharmaceutica International Ltd. | ||||||||||||||||||
Full Title: An Open-Label Study to Evaluate the Single-Dose Pharmacokinetics and Safety of Ceftobiprole in Neonate and Infant Subjects Aged ≤ 3 Months Undergoing Treatment with Systemic Antibiotics | ||||||||||||||||||
Medical condition: documented or presumed bacterial infections, or at risk of a bacterial infection | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: BE (Prematurely Ended) DE (Prematurely Ended) LT (Prematurely Ended) PL (Prematurely Ended) LV (Prematurely Ended) Outside EU/EEA | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2005-004587-23 | Sponsor Protocol Number: UZL/MBC SUBE0501 | Start Date*: 2005-12-23 |
Sponsor Name:UZ Leuven | ||
Full Title: A belgian multicenter phase II randomized trial in her2 negative metastatic breast cancer evaluating consolidation antiangiogenic therapy with SU11248 after response to taxane chemotherapy induction | ||
Medical condition: Patients must meet all of the following inclusion criteria in order to be eligible for participation in this study: • Patients with metastatic breast cancer, histologically proven • Patients receiv... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2017-004732-11 | Sponsor Protocol Number: | Start Date*: 2018-01-19 |
Sponsor Name:University of Oxford | ||
Full Title: Preventing meningitis in young people after infant immunisation: effect of a single meningococcal 4CMenB vaccine booster over 10 years of age | ||
Medical condition: Meningococcus group B disease, which can cause a variety of symptoms. The most serious of these are meningitis, and septicaemia (also known as blood poisoning). | ||
Disease: | ||
Population Age: Children, Under 18 | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2005-005592-14 | Sponsor Protocol Number: 26 | Start Date*: 2006-07-27 |
Sponsor Name:IFSgGmbH, Institute for clinical research | ||
Full Title: Double blind, placebo-controlled study to determine the safety and efficacy of erythropoietin as an add-on therapy to methylprednisolone in subjects with acute autoimmune optic neuritis (VISION PRO... | ||
Medical condition: Multiple sclerosis (MS) is a chronic disease of the central nervous system.Optic neuritis represents one of the most common and frequently the first clinical manifestation of MS. Optic neuritis is ... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2007-000550-31 | Sponsor Protocol Number: 87,1,2007_01_30 | Start Date*: 2007-10-01 |
Sponsor Name:IFS gGmbH, Universitätsmedizin Göttingen | ||
Full Title: Quetiapine vs. Placebo in alcohol relapse prevention- a pilot study | ||
Medical condition: relapse prevention of alcoholics suffering from persisting craving and/or affective symptoms | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2011-006037-42 | Sponsor Protocol Number: IB2011-03 | Start Date*: 2013-09-06 | |||||||||||
Sponsor Name:Institut Bergonié | |||||||||||||
Full Title: | |||||||||||||
Medical condition: | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-004979-35 | Sponsor Protocol Number: 05-FOR-01 SE | Start Date*: 2006-11-27 |
Sponsor Name:Andi - Ventis | ||
Full Title: A RANDOMISED, FOUR WAY CROSS-OVER STUDY TO ASSESS BRONCHODILATION, SAFETY AND TOLERABILITY OF NEW GENERIC DRY POWDER FORMOTEROL FORMULATIONS GIVEN AS CUMULATIVE DOSES FROM A NOVEL DRY POWDER INHALE... | ||
Medical condition: reversible mild asthma | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: HU (Completed) | ||
Trial results: View results |
EudraCT Number: 2009-012964-14 | Sponsor Protocol Number: XL184-203 | Start Date*: 2010-03-10 |
Sponsor Name:Exelixis Inc | ||
Full Title: A randomized discontinuation study of XL184 in subjects with advanced solid tumors | ||
Medical condition: To evaluate the efficacy of XL184 in subjects with one of the following advanced solid tumors: a. Breast Cancer b. Gastric and Gastroesophageal Junction Cancer c. Hepatocellular Carcinoma (HCC) ... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2018-001843-29 | Sponsor Protocol Number: TASTER2018 | Start Date*: 2019-05-28 | |||||||||||
Sponsor Name:NHS Greater Glasgow and Clyde [...] | |||||||||||||
Full Title: TASTER- TArgeting STEm cell Resistance An umbrella adaptive randomised multi–arm screening phase II trial for patients with 2nd/3rd generation TKI resistant chronic myeloid leukaemia | |||||||||||||
Medical condition: Chronic myeloid leukaemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-000865-13 | Sponsor Protocol Number: PMLD17102005 | Start Date*: 2006-04-17 |
Sponsor Name:Univ.Clinic of Dermatology | ||
Full Title: Evaluation of the impact from Polypodium leukotomos Extract on the Prophylaxis of Polymorphic Light Eruption (PMLE) An investigator initiated, prospective, open label study with an in Austria reg... | ||
Medical condition: Evaluation of the impact from Polypodium leukotomos Extract on the Prophylaxis of Polymorphic Light Eruption (PMLE) An investigator initiated, prospective, open label study with an in Austria reg... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2006-000683-84 | Sponsor Protocol Number: 05-FOR-02 | Start Date*: 2006-05-10 |
Sponsor Name:Andi-Ventis Ltd. | ||
Full Title: A DOUBLE BLIND, DOUBLE DUMMY, GROUP COMPARATIVE STUDY TO ASSESS THERAPEUTIC EQUIVALENCE OF A NEW GENERIC FORMOTEROL 12 uG DRY POWDER FORMULATION WITH OXIS 12uG TURBUHALER IN ADOLESCENT AND ADULT AS... | ||
Medical condition: asthma bronchiale | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: HU (Completed) SK (Completed) | ||
Trial results: View results |
EudraCT Number: 2008-005992-81 | Sponsor Protocol Number: CL-N-CSM-III/01/08 | Start Date*: 2011-03-21 | |||||||||||
Sponsor Name:Dr. F. Köhler Chemie GmbH | |||||||||||||
Full Title: A Prospective Randomized Double Blind Multicenter Phase III Study Comparing two Methods of Cardioplegia in Coronary Artery Bypass Surgery Custodiol-N versus Custodiol | |||||||||||||
Medical condition: The study population will be selected from both genders with coronary artery disease (CAD) who are to undergo cardiopulmonary bypass for coronary artery bypass surgery. The ratio of incidence for b... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-001052-39 | Sponsor Protocol Number: ARRAY-520-311 | Start Date*: 2014-11-02 | |||||||||||
Sponsor Name:Array BioPharma Inc. | |||||||||||||
Full Title: The FACTOR Study (Filanesib and Carfilzomib Treatment of Relapsed/Refractory Multiple Myeloma): A Multinational, Randomized, Open-label Phase 3 Study of Filanesib (ARRY-520) + Carfilzomib Versus ... | |||||||||||||
Medical condition: Multiple Myeloma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) AT (Completed) DE (Completed) CZ (Completed) GB (Completed) HU (Completed) ES (Completed) BE (Completed) GR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-002846-61 | Sponsor Protocol Number: ACT15319 | Start Date*: 2018-04-10 | ||||||||||||||||
Sponsor Name:Sanofi-aventis recherche & développement | ||||||||||||||||||
Full Title: A Phase 1/2 Open-label, Multi-center, Safety, Preliminary Efficacy and Pharmacokinetic (PK) Study of Isatuximab (SAR650984) in Combination with REGN2810, or Isatuximab alone, in Patients with Advan... | ||||||||||||||||||
Medical condition: - Prostate cancer - Non-small cell lung cancer | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) IT (Completed) | ||||||||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
